SR9009 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-11-07. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also marketed informally as Stenabolic |
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ |
| Molecular formula | C24H30ClN3O4S | Approximate molecular weight 492 g/mol |
| CAS Registry Number | 1379686-30-2 | Identifier for the parent compound |
| Regulatory status | Not approved for human use | Prohibited in sport by WADA |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
A meat substitute, also called a meat analogue, approximates certain aesthetic qualities (primarily texture, flavor and appearance) or chemical characteristics of a specific meat. Substitutes are often based on soybeans (such as tofu and tempeh), gluten, or peas. Whole legumes are often used as a protein source in vegetarian dishes, but are not listed here.
==== Orthodox Christian heritage ==== Among the first Christian missionaries to arrive in the Aleutian Islands was a party of ten Russian Orthodox monks and priests, who arrived in 1793. Within two years, a monk named Herman was the only survivor of that party. He settled on Spruce Island, near Kodiak Island, and often defended the rights of the Aleuts against the Russian trading companies. He is now known in the Orthodox Church as Saint Herman of Alaska. Another early Christian missionary of the Russian Orthodox Church was Father Veniaminov who arrived in Unalaska in 1824. He was named Bishop Innokentii in 1840 and moved to Sitka. He is now known in the Orthodox Church as Saint Innocent of Alaska. The principal settlements were on Unalaska Island. The oldest was Iliuliuk (also called Unalaska), settled in 1760–1775, with a customs house and an Orthodox church.
=== Corneal crystallins === Similar to lens, cornea is a transparent, avascular tissue derived from the ectoderm that is responsible for focusing light onto the retina. However, unlike lens, cornea depends on the air-cell interface and its curvature for refraction. Early immunology studies have shown that BCP 54 comprises 20–40% of the total soluble protein in bovine cornea. Subsequent studies have indicated that BCP 54 is ALDH3, a tumor and xenobiotic-inducible cytosolic enzyme, found in human, rat, and other mammals.
Rush added former Chicago keyboardist Loren Gold as a touring musician in late February 2026; his arrival to the band marked the first time since second guitarist Mitch Bossi's departure from Rush in 1972 that they have performed together as a quartet rather than a trio. In January 2026, Lee revealed in an interview with Music Radar that there was a possibility of new music from Rush upon completion of the tour, saying, "Who knows what'll happen, but I suspect some music will eventually come out", and added, "It would be fun to see what [Nilles] can do in a creative situation. Like, that would be fun. But it's all speculation until it isn't." When asked in August if the new line-up of Rush had already thought of recording new music, Lee said, "No. We have enough to do. We're still trying to remember the old songs and play them." On March 29, 2026, Rush gave a surprise performance at the 2026 Juno Awards, performing "Finding My Way" with their new line-up.
Sources: en.wikipedia.org
== External links == The MEROPS online database for peptidases and their inhibitors: I39.001[link removed] alpha+2-Macroglobulin at the U.S. National Library of Medicine Medical Subject Headings (MeSH) A2M human gene location in the UCSC Genome Browser. A2M human gene details in the UCSC Genome Browser.
=== In bats recovering from white-nose syndrome === Bats recovering from white-nose syndrome (WNS) may be the first known natural occurrence of IRIS, in a report released by the USGS. WNS is typified by a cutaneous infection of the fungus Pseudogymnoascus destructans during hibernation, when the immune system is naturally suppressed to conserve energy through the winter. This study suggests that bats undergoing an intense inflammation at the site of infection after a return to euthermia is a form of IRIS.
On 5 February the Essendon Football Club asked Australian Sports Anti-Doping Authority (ASADA) to investigate the concerns over the clubs possible use of un-approved supplements during the 2012 season. An Independent review conducted by Ziggy Switkowski regarding the Essendon Football Club governance processes was released to the public on 6 May. CEO Ian Robson hands in his resignation on 23 May. He is replaced by former Tatts Group CEO and Essendon board member Ray Gunston as the interim CEO. Chairman David Evans resigns citing health issues on 27 July. Former Toll Holdings Managing Director and Essendon board member Paul Little is elected to replace him as the new Essendon Chairman. On 27 August, the AFL charged the Essendon Football Club with breaking "Rule 1.6 - engaging in conduct that is unbecoming or likely to prejudice the interests or reputation of the Australian Football League or to bring the game of football into disrepute". There have been no player sanctions from ASADA, whose investigation is still ongoing. The following charges were handed down against club and personnel:
Sources: en.wikipedia.org
Also, cats, which are generally regarded as obligate carnivores, occasionally eat grass to regurgitate indigestible material (such as hairballs), aid with hemoglobin production, and as a laxative. Many mammals, in the absence of sufficient food requirements in an environment, suppress their metabolism and conserve energy in a process known as hibernation. In the period preceding hibernation, larger mammals, such as bears, become polyphagic to increase fat stores, whereas smaller mammals prefer to collect and stash food. The slowing of the metabolism is accompanied by a decreased heart and respiratory rate, as well as a drop in internal temperatures, which can be around ambient temperature in some cases. For example, the internal temperatures of hibernating Arctic ground squirrels can drop to −2.9 °C (26.8 °F); however, the head and neck always stay above 0 °C (32 °F). A few mammals in hot environments aestivate in times of drought or extreme heat, for example the fat-tailed dwarf lemur (Cheirogaleus medius).
=== Muscle disorders === Restless legs syndrome can be treated using clonazepam as a third-line treatment option, as the use of clonazepam is still investigational. Bruxism also responds to clonazepam in the short term. REM sleep behavior disorder responds well to low doses of clonazepam. It is also used for:
=== Songwriting process === In charge of the basic structure of the songs, Chanut or Thépegnier would then present them in rehearsal, where the other band members would develop them through a "more organic" process. Toufouti usually writes the lyrics after receiving the instrumentals. Chanut said in 2015 that he "validates his lyrics so that they totally align with the band's concept". Toufouti writes his lyrics in English for convenience. According to him, it would be more difficult in French, because of the risk of falling into excess and clichés. Furthermore, according to Chanut, the inherent fluidity of English is better suited to metal music, whereas certain French consonants are more abrupt. He added that most of the bands they listen to sing in English. Conversely, Hangman's Chair enjoys using French album or song titles for their sonority. Chanut and Thépegnier had to adapt to periods of lockdown while the rehearsal space remained closed for more than a year. They were both able to exchange ideas, as Thépegnier had his home studio under construction and Chanut had his own audio workstation. They were also able to rehearse remotely without audio latency thanks to the beta version of the NuCorder software, designed by Caste. The drum patterns that would later appear on A Loner were influenced by Thépegnier's use of an electronic drum kit during these remote songwriting sessions. From the album A Loner onwards, Chanut felt the need to write lyrics, even though the roles assigned to composing the "skeletons" of the songs remained the same.
From the early days of the development of AI, there have been arguments put forward by ELIZA creator Joseph Weizenbaum and others about whether tasks that can be done by computers actually should be done by them, given the difference between computers and humans, and between quantitative calculations and qualitative, value-based judgements. In April 2023, it was reported that image generation AI has resulted in 70% of the jobs for video game illustrators in China being lost. In July 2023, developments in generative AI contributed to the 2023 Hollywood labor disputes. Fran Drescher, president of the Screen Actors Guild, declared that "artificial intelligence poses an existential threat to creative professions" during the 2023 SAG-AFTRA strike. Voice generation AI has been seen as a potential challenge to the voice acting sector. However, a 2025 study concluded that the US labor market had so far not experienced a discernible disruption from generative AI. Another study reported that Danish workers who used chatbots saved 2.8% of their time on average, and found no significant change in earnings or hours worked.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.
No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.
The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.